Search Results - "Reguera, Juan Luis"

Real‐world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B‐cell lymphoma by Iacoboni, Gloria, Villacampa, Guillermo, Martinez‐Cibrian, Nuria, Bailén, Rebeca, Lopez Corral, Lucia, Sanchez, Jose M., Guerreiro, Manuel, Caballero, Ana Carolina, Mussetti, Alberto, Sancho, Juan‐Manuel, Hernani, Rafael, Abrisqueta, Pau, Solano, Carlos, Sureda, Anna, Briones, Javier, Martin Garcia‐Sancho, Alejandro, Kwon, Mi, Reguera‐Ortega, Juan Luis, Barba, Pere

“…Tisagenlecleucel (tisa‐cel) is a second‐generation autologous CD19‐targeted chimeric antigen receptor (CAR) T‐cell therapy approved for relapsed/refractory…”
Get full text

Best Treatment Option for Patients With Refractory Aggressive B-Cell Lymphoma in the CAR-T Cell Era: Real-World Evidence From GELTAMO/GETH Spanish Groups by Bastos-Oreiro, Mariana, Gutierrez, Antonio, Reguera, Juan Luís, Iacoboni, Gloria, López-Corral, Lucía, Terol, María José, Ortíz-Maldonado, Valentín, Sanz, Jaime, Guerra-Dominguez, Luisa, Bailen, Rebeca, Mussetti, Alberto, Abrisqueta, Pau, Hernani, Rafael, Luzardo, Hugo, Sancho, Juan-Manuel, Delgado-Serrano, Javier, Salar, Antonio, Grande, Carlos, Bento, Leyre, González de Villambrosía, Sonia, García-Belmonte, Daniel, Sureda, Anna, Pérez-Martínez, Antonio, Barba, Pere, Kwon, Mi, Martín García-Sancho, Alejandro

“…Real-world evidence comparing the efficacy of chimeric antigen receptor (CAR) T-cell therapy against that of the previous standard of care (SOC) for refractory…”
Get full text

Is CAR T a drug or a therapeutic pathway? Intention to treat versus per protocol analysis of real world studies of CAR-T cell therapy in relapsed refractory diffuse large B cell lymphoma by Di Staso, Rossana, Casadei, Beatrice, Locke, Frederick L., Jain, Michael, Voorhees, Timothy J., Kittai, Adam S., Bastos-Oreiro, Mariana, Gutiérrez, Antonio, Martin Garcia-Sancho, Alejandro, Terol, Maria Jose, Mead, Monica, Maranzano, Michael J., Iacoboni, Gloria, Barba, Pere, Kwon, Mi, Bailen, Rebeca, Reguera-Ortega, Juan Luis, Mian, Agrima, Hill, Brian, Bachy, Emmanuel, Morschhauser, Franck, Houot, Roch, Thieblemont, Catherine, Le Gouill, Steven, Masetti, Riccardo, Gori, Davide, Broccoli, Alessandro, Zinzani, Pier Luigi, Argnani, Lisa

Get full text

Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma by Kwon, Mi, Iacoboni, Gloria, Reguera, Juan Luis, Corral, Lucía López, Morales, Rafael Hernani, Ortiz-Maldonado, Valentín, Guerreiro, Manuel, Caballero, Ana Carolina, Domínguez, María Luisa Guerra, Pina, Jose Maria Sanchez, Mussetti, Alberto, Sancho, Juan Manuel, Bastos-Oreiro, Mariana, Catala, Eva, Delgado, Javier, Henriquez, Hugo Luzardo, Sanz, Jaime, Calbacho, María, Bailén, Rebeca, Carpio, Cecilia, Ribera, Jose Maria, Sureda, Anna, Briones, Javier, Hernandez-Boluda, Juan Carlos, Cebrián, Nuria Martínez, Martin, Jose Luis Diez, Martín, Alejandro, Barba, Pere

“…Axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) are CD19-targeted chimeric antigen receptor (CAR) T cells approved for relapsed/refractory…”
Get full text

Is CAR T a Drug or a Therapeutic Pathway? Systematic Review, (Re-)Estimation of Efficacy Endpoints and Metanalyses in Large B-Cell Lymphoma Real World Reports by Zinzani, Pier Luigi, Di Staso, Rossana, Casadei, Beatrice, Locke, Frederick L., Jain, Michael D., Voorhees, Timothy, Kittai, Adam S, Bastos-Oreiro, Mariana, Gutiérrez, Antonio, Martin Garcia-Sancho, Alejandro, Terol, Maria Jose, Mead, Monica, Maranzano, Michael J., Iacoboni, Gloria, Barba, Pere, Kwon, Mi, Bailen, Rebeca, Reguera, Juan Luis, Mian, Agrima, Hill, Brian T., Bachy, Emmanuel, Morschhauser, Franck, Houot, Roch, Thieblemont, Catherine, Le Gouill, Steven, Masetti, Riccardo, Gori, Davide, Argnani, Lisa

“…In everyday clinical practice, the therapeutic pathway of autologous CAR T-cell starts from leukapheresis, but the drug is infused on average 4-7 weeks later…”
Get full text

Role of allogeneic hematopoietic cell transplant for relapsed/refractory aggressive B-cell lymphomas in the CART era by Mussetti, Alberto, Bento, Leyre, Bastos-Oreiro, Mariana, Rius-Sansalvador, Blanca, Albo, Carmen, Bailen, Rebeca, Barba, Pere, Benzaquén, Ana, Briones, Javier, Caballero, Ana Carolina, Campos, António, Español, Ignacio, Ferra, Christelle, López, Sebastián Garzón, González Sierra, Pedro Antonio, Guerra, Luisa Maria, Hernani, Rafael, Iacoboni, Gloria, Jiménez-Ubieto, Ana, Kwon, Mi, Corral, Lucía López, López-Godino, Oriana, Munoz, Maria Carmen Martinez, Martínez-Cibrián, Nuria, Gómez, Juan Montoro, Pérez-Ortega, Laura, Ortí, Guillermo, Ortiz-Maldonado, Valentín, Pascual, Maria-Jesús, Perera, María, Perez, Antonio, Reguera, Juan Luis, Sanchez, Jose M., Sanz, Jaime, Torrent, Anna, Yáñez, Lucrecia, Varela, Rosario, Echechipia, Izaksun Ceberio, Caballero, Dolores, Sureda, Anna

“…Anti-CD19 chimeric antigen receptor T cells (CART) has rapidly been adopted as the standard third-line therapy to treat aggressive B-cell lymphomas (ABCL)…”
Get full text

Development and validation of the post-CAR prognostic index for large B-cell lymphoma patients after CAR-T progression in third or later line treatment by Iacoboni, Gloria, Navarro, Víctor, Sesques, Pierre, Rejeski, Kai, Bastos-Oreiro, Mariana, Serpenti, Fabio, Martin Lopez, Ana Africa, Iraola-Truchuelo, Josu, Delgado, Javier, Perez, Ariadna, Guerreiro, Manuel, Caballero, Ana Carolina, Martinez-Cibrian, Nuria, Luzardo Henriquez, Hugo, Sanchez Pina, Jose Maria, Sancho, Juan-Manuel, Ghesquieres, Hervé, Mussetti, Alberto, Lopez Corral, Lucia, Hernani, Rafael, Reguera, Juan Luis, Sureda, Anna, Bosch, Francesc, Martin Garcia-Sancho, Alejandro, Kwon, Mi, Subklewe, Marion, Kuhnl, Andrea, Bachy, Emmanuel, Barba, Pere, Villacampa, Guillermo, Abrisqueta, Pau

“…Chimeric antigen receptor (CAR) T-cell therapy fails to achieve durable responses in over 60% of relapsed/refractory (R/R) large B-cell lymphoma (LBCL)…”
Get full text

Combined or Sequential Treatment with Immune Checkpoint Inhibitors and Car-T Cell Therapies for the Management of Haematological Malignancies: A Systematic Review by Pérez-Moreno, María Antonia, Ciudad-Gutiérrez, Pablo, Jaramillo-Ruiz, Didiana, Reguera-Ortega, Juan Luis, Abdel-kader Martín, Laila, Flores-Moreno, Sandra

“…The aim of this paper was to review the available evidence on the efficacy and safety of combined or sequential use of PD-1/PD-L1 immune checkpoint inhibitors…”
Get full text

Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study by Morschhauser, Franck, Dahiya, Saurabh, Palomba, M. Lia, Martin Garcia-Sancho, Alejandro, Reguera Ortega, Juan Luis, Kuruvilla, John, Jäger, Ulrich, Cartron, Guillaume, Izutsu, Koji, Dreyling, Martin, Kahl, Brad, Ghesquieres, Hervé, Ardeshna, Kirit, Goto, Hideki, Barbui, Anna Maria, Abramson, Jeremy S., Borchmann, Peter, Fleury, Isabelle, Mielke, Stephan, Skarbnik, Alan, de Vos, Sven, Kamdar, Manali, Karmali, Reem, Viardot, Andreas, Farazi, Thalia, Fasan, Omotayo, Lymp, James, Vedal, Min, Nishii, Rina, Avilion, Ariel, Papuga, Jessica, Kumar, Jinender, Nastoupil, Loretta J.

“…An unmet need exists for patients with relapsed/refractory (R/R) follicular lymphoma (FL) and high-risk disease features, such as progression of disease within…”
Get full text

Monitoring of kinetics and exhaustion markers of circulating CAR-T cells as early predictive factors in patients with B-cell malignancies by García-Calderón, Clara Beatriz, Sierro-Martínez, Belén, García-Guerrero, Estefanía, Sanoja-Flores, Luzalba, Muñoz-García, Raquel, Ruiz-Maldonado, Victoria, Jimenez-Leon, María Reyes, Delgado-Serrano, Javier, Molinos-Quintana, Águeda, Guijarro-Albaladejo, Beatriz, Carrasco-Brocal, Inmaculada, Lucena, José-Manuel, García-Lozano, José-Raúl, Blázquez-Goñi, Cristina, Reguera-Ortega, Juan Luis, González-Escribano, María-Francisca, Reinoso-Segura, Marta, Briones, Javier, Pérez-Simón, José Antonio, Caballero-Velázquez, Teresa

“…CAR-T cell therapy has proven to be a disruptive treatment in the hematology field, however, less than 50% of patients maintain long-term response and early…”
Get full text

Treatment outcomes in patients with large B‐cell lymphoma after progression to chimeric antigen receptor T‐cell therapy by Iacoboni, Gloria, Iraola‐Truchuelo, Josu, O'Reilly, Maeve, Navarro, Víctor, Menne, Tobias, Kwon, Mi, Martín‐López, Ana África, Chaganti, Sridhar, Delgado, Javier, Roddie, Claire, Pérez, Ariadna, Norman, Jane, Guerreiro, Manuel, Gibb, Adam, Caballero, Ana Carolina, Besley, Caroline, Martínez‐Cibrián, Nuria, Mussetti, Alberto, Sanderson, Robin, Luzardo, Hugo, Iyengar, Sunil, Sánchez, Jose Maria, Jones, Ceri, Sancho, Juan‐Manuel, Barba, Pere, Latif, Anne‐Louise, López‐Corral, Lucia, Hernani, Rafael, Reguera, Juan Luis, Sureda, Anna, Garcia‐Sancho, Alejandro Martin, Bastos, Mariana, Abrisqueta, Pau, Kuhnl, Andrea

“…Over 60% of relapsed/refractory (R/R) large B‐cell lymphoma (LBCL) patients who receive chimeric antigen receptor (CAR) T cells will experience disease…”
Get full text

Combined treatment of graft versus host disease using donor regulatory T cells and ruxolitinib by Rodríguez-Gil, Alfonso, Escamilla-Gómez, Virginia, Nufer, Melanie, Andújar-Sánchez, Félix, Lopes-Ramos, Teresa, Bejarano-García, José Antonio, García-Guerrero, Estefanía, Calderón-Cabrera, Cristina, Caballero-Velázquez, Teresa, García-Calderón, Clara Beatriz, Hernández-Díaz, Paola, Reguera-Ortega, Juan Luis, Rodríguez-Torres, Nancy, Martínez-Cibrián, Nuria, Rodríguez-Barbosa, José Ignacio, Villadiego, Javier, Pérez-Simón, José Antonio

“…Donor derived regulatory T lymphocytes and the JAK1/2 kinase inhibitor ruxolitinib are currently being evaluated as therapeutic options in the treatment of…”
Get full text

P1151: BENDAMUSTINE‐CONTAINING REGIMENS CAN BE SAFELY USED AS BRIDGING IN LARGE B‐CELL LYMPHOMA PATIENTS RECEIVING CHIMERIC ANTIGEN RECEPTOR T‐CELL THERAPY by Garcia‐Calvo, Gloria Ines Iacoboni, Navarro, Victor, Lopez, Ana Africa Martin, Bastos Oreiro, Mariana, Rejeski, Kai, Aleksandra Jalowiec, Katarzyna, Amat, Paula, Ortega, Juan Luis Reguera, Blumenberg, Viktoria, Gallur, Laura, Herrero‐García, María, Roddie, Claire, Bailen, Rebeca, Benzaquen, Ana, Segura, Cecilia Carmen Carpio, López Corral, Lucía, Hernani, Rafael, Kwon, MI, Martín‐Martín, Lourdes, Subklewe, Marion, O’reilly6, Maeve, Barba Suñol, Pere

Get full text

P1382: CIRCULATING CAR‐T CELLS MONITORING OF KINETICS AND EXHAUSTION MARKERS AS PREDICTIVE FACTORS IN B‐CELL MALIGNANCIES by Sierro Martínez, Belén, Beatriz García‐Calderón, Clara, García‐Guerrero, Estefanía, Sanoja‐Flores, Luzalba, Muñoz‐García, Raquel, Ruiz‐Maldonado, Victoria, Delgado‐Serrano, Javier, Molinos‐Quintana, Águeda, Guijarro‐Albaladejo, Beatriz, Carrasco‐Brocal, Inmaculada, Manuel Lucena, Jose, Raúl García‐Lozano, José, Blázquez‐Goñi, Cristina, Ortega, Juan Luis Reguera, Francisca Gonzalez‐Escribano, María, Reinoso Segura, Marta, Briones Meijide, Javier, Josè Antonio, Perez Simon, Caballero‐Velázquez, Teresa

Get full text

Current Status of CAR-T Cell Therapy in Multiple Myeloma by Reguera-Ortega, Juan Luis, García-Guerrero, Estefanía, Pérez-Simón, Jose Antonio

“…Current data on CAR-T cell-based therapy is really promising in multiple myeloma, especially in terms of response. In heavily pretreated patients, who have…”
Get full text

Real-world evidence of brexucabtagene autoleucel for the treatment of relapsed or refractory mantle cell lymphoma by Iacoboni, Gloria, Rejeski, Kai, Villacampa, Guillermo, van Doesum, Jaap A., Chiappella, Annalisa, Bonifazi, Francesca, Lopez-Corral, Lucia, van Aalderen, Michiel, Kwon, Mi, Martínez-Cibrian, Nuria, Bramanti, Stefania, Reguera-Ortega, Juan Luis, Camacho-Arteaga, Lina, Schmidt, Christian, Marín-Niebla, Ana, Kersten, Marie José, Martin Garcia-Sancho, Alejandro, Zinzani, Pier Luigi, Corradini, Paolo, van Meerten, Tom, Subklewe, Marion, Barba, Pere

Get full text

Long-Term Impact of an Educational Antimicrobial Stewardship Program on Management of Patients with Hematological Diseases by Guisado-Gil, Ana Belén, Aguilar-Guisado, Manuela, Peñalva, Germán, Lepe, José Antonio, Espigado, Ildefonso, Rodríguez-Arbolí, Eduardo, González-Campos, José, Rodríguez-Torres, Nancy, Montero-Cuadrado, María Isabel, Falantes-González, José Francisco, Reguera-Ortega, Juan Luis, Gil-Navarro, María Victoria, Molina, José, Pérez-Simón, José-Antonio, Cisneros, José Miguel

“…Antimicrobial stewardship programs (ASPs) in hematological patients are especially relevant. However, information about ASPs in this population is scarce. For…”
Get full text

Predicting Survival after Allogeneic Hematopoietic Cell Transplantation in Myelofibrosis: Performance of the Myelofibrosis Transplant Scoring System (MTSS) and Development of a New Prognostic Model by Hernández-Boluda, Juan-Carlos, Pereira, Arturo, Alvarez-Larran, Alberto, Martín, Ana-Africa, Benzaquen, Ana, Aguirre, Lourdes, Mora, Elvira, González, Pedro, Mora, Jorge, Dorado, Nieves, Sampol, Antonia, García-Gutiérrez, Valentín, López-Godino, Oriana, Fox, María-Laura, Reguera, Juan Luis, Pérez-Encinas, Manuel, Pascual, María-Jesús, Xicoy, Blanca, Parody, Rocío, González-Pinedo, Leslie, Español, Ignacio, Avendaño, Alejandro, Correa, Juan-Gonzalo, Vallejo, Carlos, Jurado, Manuel, García-Cadenas, Irene, Osorio, Santiago, Durán, María-Antonia, Sánchez-Guijo, Fermín, Cervantes, Francisco, Piñana, José-Luis

“…•The Myelofibrosis Transplant Scoring System (MTSS) model failed to clearly delineate 4 risk groups in our series.•The MTSS can still be useful to identify a…”
Get full text

Patient-Reported Outcomes (PROs) from the Phase 2 TRANSCEND FL Study of Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory Follicular Lymphoma (FL) by Cartron, Guillaume, Martin Garcia-Sancho, Alejandro, Reguera, Juan Luis, Dahiya, Saurabh, Guo, Shien, Shi, Ling, Eliason, Laurie, Kumar, Jinender, Farazi, Thalia, Fasan, Omotayo, Izutsu, Koji

“…Background: In TRANSCEND FL (NCT04245839), a global, phase 2, open-label, single-arm, multicohort, pivotal study, the CAR T cell therapy liso-cel showed…”
Get full text

Fractionated initial infusion and booster dose of ARI0002h, a humanised, BCMA-directed CAR T-cell therapy, for patients with relapsed or refractory multiple myeloma (CARTBCMA-HCB-01): a single-arm, multicentre, academic pilot study by Oliver-Caldés, Aina, González-Calle, Verónica, Cabañas, Valentín, Español-Rego, Marta, Rodríguez-Otero, Paula, Reguera, Juan Luis, López-Corral, Lucía, Martin-Antonio, Beatriz, Zabaleta, Aintzane, Inogés, Susana, Varea, Sara, Rosiñol, Laura, López-Díaz de Cerio, Ascensión, Tovar, Natalia, Jiménez, Raquel, López-Parra, Miriam, Rodríguez-Lobato, Luis Gerardo, Sánchez-Salinas, Andrés, Olesti, Eulàlia, Calvo-Orteu, Maria, Delgado, Julio, Pérez-Simón, José Antonio, Paiva, Bruno, Prósper, Felipe, Sáez-Peñataro, Joaquín, Juan, Manel, Moraleda, José M, Mateos, María-Victoria, Pascal, Mariona, Urbano-Ispizua, Alvaro, Fernández de Larrea, Carlos

“…Chimeric antigen receptor (CAR) T-cell therapy is a promising option for patients with heavily treated multiple myeloma. Point-of-care manufacturing can…”
Get full text